Veletri

acute vasodilator testing, Pulmonary Arterial Hypertension
Treatment
1 FDA approval
20 Active Studies for Veletri

What is Veletri

EpoprostenolThe Generic name of this drug
Treatment SummaryIloprost is a medication used to treat primary pulmonary hypertension, a rare form of high blood pressure in the lungs. Iloprost is a type of prostaglandin, a substance made in the body, which causes blood vessels to widen and also prevents platelets from sticking together. It works by helping to improve blood flow and reduce the risk of blood clots.
Flolanis the brand name
Veletri Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Flolan
Epoprostenol
1995
11

Approved as Treatment by the FDA

Epoprostenol, commonly known as Flolan, is approved by the FDA for 1 uses which include Pulmonary Arterial Hypertension .
Pulmonary Arterial Hypertension

Effectiveness

How Veletri Affects PatientsEpoprostenol widens blood vessels, reduces the pressure on the heart, and stops platelets from sticking together. This causes an increase in blood flow and reduced heart rate. It can also help open up airways and reduce stomach acid and the speed of food leaving the stomach. It's not possible to accurately measure the effects of epoprostenol in humans.
How Veletri works in the bodyProstaglandins are molecules found throughout the body that help perform many functions. Epoprostenol (PGI2) is one type of prostaglandin, and it helps prevent the blood from clotting. It does this by activating a series of proteins, which eventually inhibit platelet activation and keep myosin light-chain kinase from becoming active. This process also causes smooth muscle relaxation and vasodilation. PGI2 works as a natural contrast to thromboxane A2, another molecule that can cause blood to clot.

When to interrupt dosage

The endorsed dosage of Veletri is contingent upon the identified affliction. The dose fluctuates as per the method of delivery indicated in the table beneath.
Condition
Dosage
Administration
Pulmonary Arterial Hypertension
1.5 mg, 0.5 mg, , 0.15 mg/mL, 0.05 mg/mL, 1.5 mg/mL
, Injection, powder, for solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, for solution
acute vasodilator testing
1.5 mg, 0.5 mg, , 0.15 mg/mL, 0.05 mg/mL, 1.5 mg/mL
, Injection, powder, for solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, for solution

Warnings

Veletri has one contraindication, and its intake should be avoided while encountering any of the conditions listed in the following table.Veletri Contraindications
Condition
Risk Level
Notes
Left Ventricular Ejection Fraction
Do Not Combine
There are 20 known major drug interactions with Veletri.
Common Veletri Drug Interactions
Drug Name
Risk Level
Description
Abrocitinib
Major
The risk or severity of bleeding and thrombocytopenia can be increased when Epoprostenol is combined with Abrocitinib.
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Epoprostenol.
Amifostine
Major
Epoprostenol may increase the hypotensive activities of Amifostine.
Andexanet alfa
Major
The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Epoprostenol.
Anti-inhibitor coagulant complex
Major
The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Epoprostenol.
Veletri Toxicity & Overdose RiskSymptoms of epoprostenol overdose may include redness in the face, headache, low blood pressure, nausea, vomiting, and diarrhea. If taken in large doses, it can be lethal to mice and rats. Signs of acute poisoning may include sluggishness, lack of coordination, difficulty staying upright, slow breathing, and lower than normal body temperature.

Veletri Novel Uses: Which Conditions Have a Clinical Trial Featuring Veletri?

52 active trials are currently in progress to assess the potential of Veletri in treating Pulmonary Arterial Hypertension.
Condition
Clinical Trials
Trial Phases
Pulmonary Arterial Hypertension
53 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Phase 4, Early Phase 1
acute vasodilator testing
0 Actively Recruiting

Veletri Reviews: What are patients saying about Veletri?

5Patient Review
4/23/2017
Veletri for Pulmonary Arterial Hypertension
I've been using this medication for three years now, and last December saw my best results yet in terms of a six minute walk. I do experience some side effects like jaw pain andoccasional headaches, but nothing that's unmanageable.
5Patient Review
2/7/2012
Veletri for Pulmonary Arterial Hypertension
I believe there are more side effects to this medicine than we currently know. Even still, I found it to be effective and would recommend it.
4.3Patient Review
7/27/2012
Veletri for Pulmonary Arterial Hypertension
Flolan was a lifesaver when I was first diagnosed with PH in 2005. I continued using it until 2011 when I switched to Veletri. It's been just as effective, but without the ice packs! The only downside is that it comes with the same side effects (jaw pain and foot pain).
4Patient Review
2/28/2012
Veletri for Pulmonary Arterial Hypertension
I definitely have more energy and can do more since starting this treatment. It's not the most convenient, but it's worth it to me.
2.7Patient Review
10/7/2015
Veletri for Pulmonary Arterial Hypertension
I've been using Veletri for a little over a year and it has helped to bring my pulmonary pressure back down to a normal range. However, the 24/7 infusion pump is really inconvenient, as are the side effects. These include constant nausea, diarrhea, all-over body aches and pains, and jaw pain that starts after just a few bites of food. I would love to find a medication with less side effects.

Patient Q&A Section about veletri

How is VELETRI administered?

"VELETRI is administered through a central venous catheter by continuous intravenous infusion using an ambulatory infusion pump. It can also be initiated peripherally. The infusion sets used should have an in-line 0.22 micron filter." - Anonymous Online Contributor

Unverified Answer

How long does it take for VELETRI to work?

"People who took epoprostenol for 8 or 12 weeks showed an improvements in their ability to walk long distances within 6 minutes. In some cases, people showed these improvements in as little as 1 week. In addition, these people also reported reduced symptoms, such as fatigue and shortness of breath." - Anonymous Online Contributor

Unverified Answer

What happens if you stop VELETRI?

"The symptoms of abruptly stopping VELETRI use include lightheadedness, weakness, and difficulty breathing. Because VELETRI has an effect on blood vessels, an overdose can lead to low blood pressure, loss of consciousness, nausea, diarrhea, vomiting, facial flushing, headache, and a fast heart rate." - Anonymous Online Contributor

Unverified Answer

What is VELETRI used for?

"VELETRI is administered intravenously and is used to treat adults with severe pulmonary arterial hypertension. This is a condition whereby the blood pressure in the vessels between the heart and lungs is too high." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Veletri

Image of Indiana University Health in Indianapolis, United States.
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Low Dose AV-101for Pulmonary Arterial Hypertension

Indianapolis, IN
18 - 75
All Sexes
IMPAHCT-FUL: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (LTE) Trial is a follow up study to establish the long-term safety of AV-101. The long-term effects of AV-101 on efficacy measures will also be assessed. Subjects who successfully complete the 24-week placebo-controlled parent trial (AV-101-002) will be offered the opportunity to continue into this LTE study. Subjects who enroll in the study will receive one of three active AV-101 doses until such time as the optimal dose has been selected in the parent study.
Phase 2 & 3
Recruiting
Indiana University HealthAerovate Therapeutics
Have you considered Veletri clinical trials? We made a collection of clinical trials featuring Veletri, we think they might fit your search criteria.
Have you considered Veletri clinical trials? We made a collection of clinical trials featuring Veletri, we think they might fit your search criteria.
Have you considered Veletri clinical trials? We made a collection of clinical trials featuring Veletri, we think they might fit your search criteria.